Leukemia
Leukemia
Advertisement
Cecilia BrownLeukemia | July 8, 2024
It is now “first and only” bispecific T-cell engager therapy approved for consolidation treatment regardless of MRD ...
Read More
Christophe Willekens, MDConferences | July 8, 2024
Hear expert insights on managing treatment for these patients and the key signs and symptoms to monitor.
Cecilia BrownConferences | May 7, 2024
There is a “lack of consistency” among patient-reported outcome measures used to evaluate CML treatments.
Cecilia BrownConferences | April 5, 2024
The analysis of 10 clinical trials and 1 prospective cohort study provides a "benchmark for future studies" of the treatment.
Cecilia BrownConferences | April 5, 2024
A team studied real-world concordance with NCCN guidelines for diagnostic tests, workup during observation, and treatment.
Cecilia BrownConferences | April 9, 2024
Even highly educated patients feel "inadequately informed about the purpose, implications, and language around testing."
Cecilia BrownConferences | April 9, 2024
It was important to develop the model because fatigue has been an "overlooked side effect" due to its "subjective nature."
Cecilia BrownLeukemia | March 26, 2024
The label expansion was supported by data from the phase III PhALLCON study.
Cecilia BrownHematology & Blood Cancer | April 16, 2024
Educational content focused on the pre-HSCT work-up process, chemotherapy, and transplant admission expectations.
Cecilia BrownLeukemia | March 8, 2024
The approval is for pediatric patients older than 1 year with relapsed or refractory CD22-positive B-cell precursor ALL.
Cecilia BrownHematology & Blood Cancer | March 6, 2024
Nurses reported that they were “keenly aware of how disruptive the environment is for patients and their families."
Cecilia BrownNews | February 7, 2024
Psychosocial care and support are critical parts of cancer care, according to the International Psycho-Oncology Society.
Cecilia BrownHematology & Blood Cancer | January 15, 2024
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Cecilia BrownHematology & Blood Cancer | January 4, 2024
Anastasia Marie Santiago, DNP, APRN, FNP-BC, AOCNP, shares her experiences and several critical pieces of advice.
Abbey Fueger, BA, BSN, RN, CCRPConferences | December 28, 2023
A clinical trial nurse navigator at The Leukemia & Lymphoma Society discusses real-world data on CLL.
Cecilia BrownConferences | November 15, 2023
Josie Montegaard, NP, who spoke about CLL at JADPRO Live 2023, discusses how she hopes to see the field move forward.
Cecilia BrownNews | February 8, 2024
Anastasia Marie Santiago, DNP, APRN, FNP-BC, AOCNP, explains what Nurse Practitioner Week means to her.
Cancer Nursing Today EditorsConferences | November 17, 2023
APPs play a vital role in early recognition of symptoms of rheumatologic autoimmune diseases in patients with CLL.
Patrick DalyConferences | October 17, 2023
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Patrick DalyConferences | October 17, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Advertisement
Advertisement
Advertisement